AIM: To investigate the effects of the heme oxygenase (HO)-1/carbon monoxide system on iron deposition and portal pressure in rats with hepatic fibrosis induced by bile duct ligation (BDL). METHODS: Male Sprague-Dawley rats were divided randomly into a Sham group, BDL group, Fe group, deferoxamine (DFX) group, zinc protoporphyrin (ZnPP) group and cobalt protoporphyrin (CoPP) group. The levels of HO-1 were detected using different methods. The serum carboxyhemoglobin (COHb), iron, and portal vein pressure (PVP) were also quantified. The plasma and mRNA levels of hepcidin were measured. Hepatic fibrosis and its main pathway were assessed using Van Gieson's stain, hydroxyproline, transforming growth factor-β1 (TGF-β1), nuclear factor-E2-related factor 2 (Nrf2), matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of metalloproteinase-1 (TIMP-1). RESULTS: Serum COHb and protein and mRNA expression levels of HO-1 and Nrf2 were increased in the BDL group compared with the Sham group and were much higher in the CoPP group. The ZnPP group showed lower expression of HO-1 and Nrf2 and lower COHb. The levels of iron and PVP were enhanced in the BDL group but were lower in the ZnPP and DFX groups and were higher in the CoPP and Fe groups. Hepcidin levels were higher, whereas superoxide dismutase levels were increased and malonaldehyde levels were decreased in the ZnPP and DFX groups. The ZnPP group also showed inhibited TGF-β1 expression and regulated TIMP-1/MMP-2 expression, as well as obviously attenuated liver fibrosis. CONCLUSION: Reducing hepatic iron deposition and CO levels by inhibiting HO-1 activity though the Nrf2/Keap pathway could be helpful in improving hepatic fibrosis and regulating PVP.
AIM: To investigate the effects of the heme oxygenase (HO)-1/carbon monoxide system on iron deposition and portal pressure in rats with hepatic fibrosis induced by bile duct ligation (BDL). METHODS: Male Sprague-Dawley rats were divided randomly into a Sham group, BDL group, Fe group, deferoxamine (DFX) group, zinc protoporphyrin (ZnPP) group and cobalt protoporphyrin (CoPP) group. The levels of HO-1 were detected using different methods. The serum carboxyhemoglobin (COHb), iron, and portal vein pressure (PVP) were also quantified. The plasma and mRNA levels of hepcidin were measured. Hepatic fibrosis and its main pathway were assessed using Van Gieson's stain, hydroxyproline, transforming growth factor-β1 (TGF-β1), nuclear factor-E2-related factor 2 (Nrf2), matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of metalloproteinase-1 (TIMP-1). RESULTS: Serum COHb and protein and mRNA expression levels of HO-1 and Nrf2 were increased in the BDL group compared with the Sham group and were much higher in the CoPP group. The ZnPP group showed lower expression of HO-1 and Nrf2 and lower COHb. The levels of iron and PVP were enhanced in the BDL group but were lower in the ZnPP and DFX groups and were higher in the CoPP and Fe groups. Hepcidin levels were higher, whereas superoxide dismutase levels were increased and malonaldehyde levels were decreased in the ZnPP and DFX groups. The ZnPP group also showed inhibited TGF-β1 expression and regulated TIMP-1/MMP-2 expression, as well as obviously attenuated liver fibrosis. CONCLUSION: Reducing hepatic iron deposition and CO levels by inhibiting HO-1 activity though the Nrf2/Keap pathway could be helpful in improving hepatic fibrosis and regulating PVP.
Entities:
Keywords:
Bile duct ligation; Carboxyhemoglobin; Heme oxygenase-1; Hepcidin; Iron accumulation; Oxidative stress; Portal vein pressure
Authors: Jeanne M Horowitz; Paul Nikolaidis; Zong-Ming E Chen; Evan Siegelman; Akash Garg; Chun Feng; Frank H Miller Journal: J Magn Reson Imaging Date: 2011-03 Impact factor: 4.813
Authors: F Amersi; R Buelow; H Kato; B Ke; A J Coito; X D Shen; D Zhao; J Zaky; J Melinek; C R Lassman; J K Kolls; J Alam; T Ritter; H D Volk; D G Farmer; R M Ghobrial; R W Busuttil; J W Kupiec-Weglinski Journal: J Clin Invest Date: 1999-12 Impact factor: 14.808
Authors: Zeid Kayali; Rostislav Ranguelov; Frank Mitros; Chrisandra Shufelt; Farshad Elmi; Stephen C Rayhill; Warren N Schmidt; Kyle E Brown Journal: Liver Int Date: 2005-02 Impact factor: 5.828
Authors: Zia A Khan; Yousef P Barbin; Mark Cukiernik; Paul C Adams; Subrata Chakrabarti Journal: Can J Physiol Pharmacol Date: 2004-07 Impact factor: 2.273
Authors: Marta B Afonso; Pedro M Rodrigues; André L Simão; Dimitry Ofengeim; Tânia Carvalho; Joana D Amaral; Maria M Gaspar; Helena Cortez-Pinto; Rui E Castro; Junying Yuan; Cecília M P Rodrigues Journal: Cell Death Dis Date: 2016-09-29 Impact factor: 8.469